Episodios
-
Pfizer's stock, symbol PFE, has been underperforming the broader market over the past 52 weeks, with a drop of 3.1% compared to the S&P 500 Index's 22.6% rally. As of January 29, 2025, the closing stock price for Pfizer is 26.62 dollars.
The trading volume for Pfizer on January 30, 2025, was 32,289,570 shares, with the day's high at 27.01 dollars and the day's low at 26.58 dollars. This volume is in line with the average daily trading volume, indicating stable investor interest.
Recent news and announcements have highlighted challenges facing Pfizer, including declining COVID-19 product sales, pricing pressures, and increased competition in key markets. Concerns over patent expirations, regulatory uncertainties, and slower-than-expected growth in new drug launches have also weighed on investor sentiment.
Major analyst updates show a cautiously optimistic outlook for Pfizer's stock. The average 12-month price forecast from 12 analysts is 32.17 dollars, with a low estimate of 25 dollars and a high estimate of 45 dollars. This average target predicts an increase of 23.15% from the current stock price. The consensus rating among analysts is "Buy," indicating that the stock is likely to outperform the market over the next twelve months.
Long-term forecasts vary significantly, with some predicting strong growth and others anticipating a decline. For instance, one forecast suggests that Pfizer stock may reach 38.18 dollars by 2028, while another predicts a possible decline to at least 15.164 dollars.
Overall, Pfizer's stock is currently facing headwinds due to industry challenges and competitive pressures. However, analysts remain optimistic about the company's strong product lineup and potential for future growth, making it a stock to watch for investors interested in the pharmaceutical sector. -
Pfizer's stock price as of January 24, 2025, is 26.09 dollars. The recent trading volume has been around 36 million shares, which is close to the average trading volume. However, on December 20, 2024, the trading volume spiked to 116 million shares, indicating a significant increase in investor activity.
Recent news and announcements about Pfizer include the company's strong product lineup, including vital pharmaceuticals and promising new treatments and vaccines. Analysts have a cautiously optimistic outlook for Pfizer's stock, anticipating potential growth in its value. However, the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors can influence stock trajectories.
Major analyst updates include WalletInvestor's prediction that Pfizer stock will fluctuate in a sideways channel in 2025, ranging from 23.837 to 28.105 dollars, with a level of 24.897 dollars expected at the end of the year. CoinPriceForecast expects strong growth, suggesting that Pfizer stock may reach 38.18 dollars by 2028.
The short interest ratio for Pfizer is 1.8, indicating that it would take 1.8 days of the average trading volume to cover all short positions. The short interest has decreased by 11.32% from the previous month, with 75.71 million shares currently shorted.
Pfizer's financial position is strong, with a market capitalization of 149 billion dollars and revenue of 58 billion dollars. The company's stock has experienced a decline in 2024, with a yearly close of 26.530 dollars, down 2.24% from the previous year.
Overall, Pfizer's stock is expected to experience moderate growth in the short term, with potential for stronger growth in the long term. Investors should be cautious of industry dynamics and broader economic factors that can influence the stock's trajectory. -
¿Faltan episodios?
-
Pfizer's stock price as of January 28, 2025, is $26.79, reflecting a decrease of $0.10 or 0.37 percent since the previous trading session. The company's stock performance has been muted, with a 5% loss in 2024 compared to the broader S&P 500 index's 23% gain.
Recent news includes Pfizer's acquisition of Seagen in December 2023, which has contributed to top-line growth. The company has also seen strong performances from its drugs Vyndaqel and Abrysvo, with Vyndaqel sales up 66% year-over-year to $3.9 billion for the nine-month period ending September 2024. Additionally, Pfizer has been focused on cutting costs, aiming to achieve $4 billion in savings for 2024.
Analysts have mixed views on Pfizer's stock. The average 12-month price forecast from 12 analysts is $32.17, with a low estimate of $25 and a high estimate of $45. This represents a potential increase of 23.15% from the current stock price. However, some analysts have expressed concerns about the impact of a decline in annual Covid-19 vaccine sales and increased competition for some of Pfizer's drugs.
Pfizer's financial health is strong, with a market capitalization above industry averages and a net margin of 25.22%, indicating efficient cost management. However, the company's return on equity is below industry benchmarks, signaling potential difficulties in generating satisfactory returns for shareholders.
In terms of trading volume, Pfizer's recent trading volume is not significantly different from its average. The company's 52-week high stock price is $31.54, which is 21.3% above the current share price, and the 52-week low stock price is $24.48, which is 5.9% below the current share price.
Overall, Pfizer's stock performance is expected to be influenced by a mix of positives and negatives in 2025, including the potential loss of patent protection for its blockbuster arthritis drug Xeljanz and continued growth from its other drugs. Analysts are looking for signs of improvement in profitability, and the company's recent cost-cutting efforts and acquisitions are expected to contribute to its financial health. -
Pfizer's stock, symbol PFE, has been a focus of interest for investors and analysts. As of January 17, 2025, the stock price closed at 26.30 dollars, with a slight decrease of 0.72 percent. After-hours trading saw a minor increase of 0.27 percent to 26.37 dollars.
Recent news includes Pfizer's full-year 2025 guidance, where the company anticipates revenues to be in the range of 61.0 to 64.0 billion dollars. This includes expectations of revenues from COVID-19 products being largely consistent with 2024, excluding non-recurring revenue for Paxlovid. The company also expects full-year 2025 operational revenue growth to be approximately flat to 5 percent from the midpoint of 2024 baseline guidance.
Analysts have provided updates on Pfizer's stock forecast. The average 12-month price target from 12 analysts is 32.17 dollars, with a low estimate of 25 dollars and a high estimate of 45 dollars. This suggests a potential increase of 23.15 percent from the current stock price. The consensus among analysts is a "Buy" rating, indicating that the stock is likely to outperform the market over the next twelve months.
Trading volume and average volume data are not provided in real-time, but historical data shows that Pfizer's stock has been trending up since April 2024, with each new low being higher than the previous one. This indicates a sustainable bullish trend with possible corrections as new resistance levels are reached.
In the long term, forecasts vary significantly. Some predict strong growth, suggesting that Pfizer stock may reach 38.18 dollars by 2028, while others predict a possible decline to at least 15.164 dollars. However, the medium-term outlook looks positive, with potential for continued growth within the ascending channel.
Recent price forecasts for the end of 2025 include predictions of 38.20 dollars in November and 38.79 dollars in December, indicating a slight increase. However, January 2026 forecasts a decline to 35.45 dollars, a decrease of 8.6 percent.
Overall, Pfizer's stock is seen as a cautiously optimistic investment, with a strong product lineup and promising new treatments and vaccines. However, investors should be aware of the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors, which can influence stock trajectories. -
Pfizer's stock, symbol PFE, has been experiencing moderate volatility in recent times. As of January 17, 2025, the stock closed at twenty-six dollars and thirty cents, with a daily change of minus zero point seventy-two percent. This trend reflects market pressure but also presents an opportunity for investors to enter at a lower price than the previous peak of twenty-seven dollars and fifty-seven cents.
The trading volume has been significant, with a three-month average volume of forty-three million one hundred forty thousand shares, indicating good liquidity for the stock. High trading volumes, such as one hundred sixteen million thirty-four thousand shares on December 20, 2024, suggest investor interest in this stock.
Recent news and announcements have been centered around Pfizer's strong product lineup, including vital pharmaceuticals and promising new treatments and vaccines. Analysts have a cautiously optimistic outlook for Pfizer's stock, anticipating potential growth despite industry sensitivity to regulatory shifts, competitive dynamics, and broader economic factors.
Major analyst updates include a consensus "Buy" rating from thirteen stock analysts, with an average twelve-month price target of thirty-two dollars and seventeen cents. This predicts an increase of twenty-three point fifteen percent from the current stock price. The low estimate is twenty-five dollars, and the high estimate is forty-five dollars.
In terms of recent price movements, Pfizer's stock has been trending up since April 2024, with each new low being higher than the previous one. The price moves in an ascending channel, regularly bouncing off the resistance and support lines, indicating a sustainable bullish trend with possible corrections as new resistance levels are reached.
Overall, Pfizer's stock remains attractive as a defensive investment in the healthcare sector, with solid financial indicators and attractive dividends for investors. The long-term outlook for Pfizer stock looks positive, with potential for continued growth within the ascending channel. -
Pfizer's stock price as of January 22, 2025, is twenty-six dollars and one cent. The stock has seen a decline in recent months, with the fifty-two-week high being thirty-one dollars and fifty-four cents, which is twenty-one point three percent above the current share price.
In terms of trading volume, recent data shows that the volume has been fluctuating, with seventeen point two five million shares traded on one day and fifteen point one eight million shares traded on another. However, the average trading volume is not provided in the available data.
Recently, Pfizer provided its full-year 2025 guidance, anticipating revenues to be in the range of sixty-one billion to sixty-four billion dollars. The company also expects full-year 2025 adjusted diluted EPS to be in the range of two dollars and eighty cents to three dollars. Additionally, Pfizer announced that it has achieved its goal of four billion dollars in net cost savings through 2024 and anticipates an additional five hundred million dollars in savings in 2025.
Major analyst updates include a consensus price target of thirty-seven dollars based on the ratings of twenty-four analysts. The high price target is sixty dollars issued by Goldman Sachs, while the low is twenty-five dollars issued by Wolfe Research. Recent analyst ratings include a neutral rating from UBS with a price target of twenty-nine dollars, and a maintained rating from Truist Securities and Guggenheim with an average price target of thirty-one dollars and thirty-three cents.
Other relevant news includes Pfizer's efforts to improve its gross margin performance through its manufacturing optimization program, which is expected to deliver initial net cost savings in the latter part of 2025. The company's strong product lineup, including vital pharmaceuticals and promising new treatments and vaccines, also supports a cautiously optimistic outlook for Pfizer's stock.
Long-term forecasts vary significantly, with some predicting strong growth and others anticipating a decline. However, the medium-term trend has been positive, with the stock moving in an ascending channel and regularly bouncing off resistance and support lines. This indicates a sustainable bullish trend with possible corrections as new resistance levels are reached. -
Pfizer's stock price as of January 22, 2025, is 26.01 dollars. The trading volume on January 21, 2025, was 6,549,794 shares, which is a significant decline of 79% from the average session volume of 31,176,404 shares.
Recent news on Pfizer includes the company's shares trading up 0.5% during mid-day trading on January 21, 2025, reaching a high of 26.64 dollars and last trading at 26.43 dollars. This slight increase follows a period of cautious optimism among analysts and investors regarding Pfizer's stock forecast.
Major analyst updates include Evercore ISI raising Pfizer's rating to "strong-buy" in a research report on October 30, 2024. Guggenheim reduced their target price on Pfizer from 35 dollars to 33 dollars and maintained a "buy" rating in a research note on December 11, 2024. Citigroup initiated coverage on Pfizer with a "neutral" rating and a price target in a research note on October 25, 2024.
The consensus among analysts leans towards a positive outlook for Pfizer's stock, with an average 12-month price target of 32.17 dollars, indicating a potential increase of 21.44% from the current stock price. The stock has been trending upwards since April 2024, moving within an ascending channel and regularly bouncing off resistance and support lines, suggesting a sustainable bullish trend with possible corrections.
Pfizer's strong product lineup, including vital pharmaceuticals and promising new treatments and vaccines, underpins the optimism. However, investors should be aware of the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors that can influence stock trajectories.
In the long term, forecasts vary significantly, with some predicting strong growth and others anticipating a decline. For instance, CoinPriceForecast expects Pfizer stock to reach 38.18 dollars by 2028, while WalletInvestor predicts a possible decline to at least 15.164 dollars. The 52-week high stock price is 31.54 dollars, which is 19.4% above the current share price, and the 52-week low stock price is 24.48 dollars, which is 7.3% below the current share price. -
Pfizer's stock price as of January 22, 2025, is $26.41, reflecting a slight increase from the previous day's closing price of $26.30. The trading volume on January 21, 2025, was 6,549,794 shares, which is a significant decline of 79% from the average session volume of 31,176,404 shares.
Recent news on Pfizer includes the company's stock performance in the Indian market, where Pfizer Ltd. saw a 3.05% decline in its stock price on January 22, 2025, closing at Rs 4791. This contrasts with the broader market, as the Sensex recorded a modest gain of 0.19% on the same day.
In terms of analyst updates, Evercore ISI raised Pfizer's rating to "strong-buy" in a research report on October 30, 2024. Guggenheim reduced their target price on Pfizer from $35.00 to $33.00 and maintained a "buy" rating in a research note on December 11, 2024. Citigroup initiated coverage on Pfizer with a "neutral" rating and a price target in a research note on October 25, 2024.
The consensus among analysts is generally positive, with an average target price of $32.17, indicating a potential increase of 21.44% from the current stock price. The average analyst rating for Pfizer stock from 13 stock analysts is "Buy," suggesting that the stock is likely to outperform the market over the next twelve months.
Looking at the long-term outlook, forecasts vary significantly. WalletInvestor predicts a slight decline in Pfizer stock in 2025, with a forecast ranging from $23.837 to $28.105. In contrast, CoinPriceForecast expects strong growth, suggesting that Pfizer stock may reach $38.18 by 2028.
Pfizer's historical stock performance shows a 52-week high of $31.54, which is 19.4% above the current share price, and a 52-week low of $24.48, which is 7.3% below the current share price. The average Pfizer stock price for the last 52 weeks is $27.81.
Overall, Pfizer's stock is navigating a challenging market environment, but the consensus among analysts leans towards a cautiously optimistic outlook, driven by the company's strong product lineup and promising new treatments and vaccines. However, investors should remain aware of the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors. -
Pfizer's stock price as of January 17, 2025, is 26.30 dollars, with a slight decrease of 0.19 dollars from the previous day. The trading volume is not significantly different from the average, indicating stable investor interest.
Recent news includes Pfizer's full-year 2025 guidance, which anticipates revenues in the range of 61.0 to 64.0 billion dollars. This includes expectations of consistent revenues from COVID-19 products, excluding non-recurring items from 2024. The company also expects adjusted diluted EPS to be in the range of 2.80 to 3.00 dollars, reflecting operational growth of 10% to 18% from the midpoint of 2024 guidance[1].
Major analyst updates include a consensus "Buy" rating from 13 stock analysts, with an average 12-month price target of 32.17 dollars. This suggests a potential increase of 21.44% from the current stock price. Analysts from various firms have provided price targets ranging from 25 to 45 dollars, indicating a generally positive outlook for Pfizer's stock[3].
Other relevant news includes Pfizer's ongoing cost realignment program, which has achieved 4.0 billion dollars in net cost savings through 2024 and anticipates an additional 500 million dollars in savings in 2025. The company's manufacturing optimization program is also on track to deliver initial net cost savings in the latter part of 2025, aiming to improve gross margin performance[2].
Long-term forecasts vary, with some predicting strong growth and others suggesting a decline. For instance, CoinPriceForecast expects Pfizer stock to reach 31.12 dollars by mid-2025 and 31.61 dollars by year-end, indicating steady growth. In contrast, WalletInvestor predicts a slight decline in 2025, with the stock price expected to be around 24.897 dollars by year-end[4].
Overall, Pfizer's stock appears to be in a stable position, with a strong product lineup and positive analyst outlook. However, investors should remain cautious due to the pharmaceutical industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors. -
Pfizer's stock price as of January 17, 2025, is $26.30, with a trading volume of 26,634,696 shares. This volume is slightly below the average trading volume seen in the first week of January 2025, which ranged from 32,836,862 to 43,950,971 shares.
Recent news and announcements include Pfizer's participation in the 2025 J.P. Morgan Healthcare Conference, which could potentially spark biotech mergers and acquisitions. Additionally, Pfizer's strategic initiatives and growth prospects have driven a buy rating from various analysts.
Major analyst updates include a consensus price target of $37 based on the ratings of 24 analysts. The most recent analyst ratings were released by UBS, Truist Securities, and Guggenheim on January 8, 2025, December 18, 2024, and December 11, 2024, respectively. These ratings imply a 17.62% upside for Pfizer Inc from the current price.
Pfizer's stock has underperformed the market in the last year, with a price return of -2.8% compared to the SPY ETF's gain of +25.8%. The stock has also underperformed in the last three months and two weeks, returning -8.4% and -1.2%, respectively.
Long-term forecasts vary significantly, with CoinPriceForecast expecting strong growth to $38.18 by 2028, while WalletInvestor predicts a possible decline to at least $15.164. PandaForecast anticipates sustained growth throughout 2025, with the price stabilizing in January and reaching highs above $30 in February and March, and potentially reaching $40.15 by December.
Pfizer's 52-week high stock price is $31.54, which is 19.4% above the current share price, and the 52-week low stock price is $24.48, which is 7.3% below the current share price. The average Pfizer stock price for the last 52 weeks is $27.81. -
Pfizer's stock price as of January 17, 2025, is $26.30, with a trading volume of 8,429,549 shares during mid-day trading, representing a 72% decline from the average session volume of 30,452,807 shares.
Recent news and announcements include several analyst updates and price target changes. Sanford C. Bernstein initiated coverage on Pfizer with a "market perform" rating and a $32.00 target price. UBS Group reduced their price objective from $31.00 to $29.00 and maintained a "neutral" rating. Guggenheim lowered their target price from $35.00 to $33.00 and kept a "buy" rating.
The consensus price target for Pfizer is $37, based on ratings from 24 analysts, with the high being $60 issued by Goldman Sachs and the low being $25 issued by Wolfe Research. The three most recent analyst ratings from UBS, Truist Securities, and Guggenheim imply a 17.62% upside for Pfizer.
Pfizer's financial and market position indicates a cautiously optimistic outlook for its stock, driven by its strong product lineup and promising new treatments and vaccines. However, the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors can influence stock trajectories.
Long-term forecasts vary significantly, with CoinPriceForecast expecting strong growth to $38.18 by 2028, while WalletInvestor predicts a possible decline to at least $15.164. PandaForecast anticipates sustained growth throughout 2025, with prices stabilizing in January and reaching highs above $30 in February and March, and potentially reaching $40.15 by December.
Pfizer's 52-week high stock price is $31.54, which is 19.4% above the current share price, and the 52-week low stock price is $24.48, which is 7.3% below the current share price. The average Pfizer stock price for the last 52 weeks is $27.81. -
Pfizer's stock price as of January 14, 2025, is twenty-six dollars and forty-one cents. The trading volume is thirty-two point three million shares, slightly above its average of thirty-one point two million shares.
Recent news includes Pfizer's invitation to the public to view and listen to a webcast of its discussion at a healthcare conference on January 6, 2025. Additionally, the FDA issued its first draft guidance on the use of AI in drug and medical device development, which could impact Pfizer's future research and development efforts.
Major analyst updates include a consensus price target of thirty-seven dollars based on the ratings of twenty-four analysts, with the high being sixty dollars issued by Goldman Sachs on December 13, 2022, and the low being twenty-five dollars issued by Wolfe Research on November 15, 2024. The three most recent analyst ratings were released by UBS, Truist Securities, and Guggenheim on January 8, 2025, December 18, 2024, and December 11, 2024, respectively, with an average price target of thirty-one dollars and thirty-three cents, suggesting a seventeen point six two percent upside.
Pfizer's stock forecast for 2025 and beyond is cautiously optimistic, driven by its strong product lineup and promising new treatments and vaccines. However, the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors could influence stock trajectories. WalletInvestor predicts a slight decline in Pfizer stock in 2025, ranging from twenty-three dollars and eighty-three cents to twenty-eight dollars and ten cents, with a level of twenty-four dollars and eighty-nine cents expected at the end of the year.
Pfizer's fifty-two-week high stock price is thirty-one dollars and fifty-four cents, which is nineteen point four percent above the current share price, and its fifty-two-week low stock price is twenty-four dollars and forty-eight cents, which is seven point three percent below the current share price. The average Pfizer stock price for the last fifty-two weeks is twenty-seven dollars and eighty-one cents. -
Pfizer's stock price as of January 14, 2025, is twenty-six dollars and forty-one cents, indicating a thirty-seven percent discount from its fair value of seventy-seven dollars[1]. The trading volume is thirty-two point three million shares, slightly above its average of thirty-one point two million shares[1].
Recent news includes Pfizer's invitation to the public to view and listen to a webcast of its discussion at a healthcare conference on January 6, 2025[2]. Additionally, the FDA issued its first draft guidance on the use of AI in drug and medical device development, which could impact Pfizer's future research and development efforts[2].
Major analyst updates include a consensus price target of thirty-seven dollars based on the ratings of twenty-four analysts, with the high being sixty dollars issued by Goldman Sachs on December 13, 2022, and the low being twenty-five dollars issued by Wolfe Research on November 15, 2024[3]. The three most recent analyst ratings were released by UBS, Truist Securities, and Guggenheim on January 8, 2025, December 18, 2024, and December 11, 2024, respectively, with an average price target of thirty-one dollars and thirty-three cents, suggesting a seventeen point six two percent upside[3].
Pfizer's stock forecast for 2025 and beyond is cautiously optimistic, driven by its strong product lineup and promising new treatments and vaccines[4]. However, the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors could influence stock trajectories[4]. WalletInvestor predicts a slight decline in Pfizer stock in 2025, ranging from twenty-three dollars and eighty-three cents to twenty-eight dollars and ten cents, with a level of twenty-four dollars and eighty-nine cents expected at the end of the year[4].
In terms of historical performance, Pfizer's fifty-two-week high stock price is thirty-one dollars and fifty-four cents, which is sixteen point three percent above the current share price, and its fifty-two-week low stock price is twenty-four dollars and forty-eight cents, which is nine point eight percent below the current share price[5]. The average Pfizer stock price for the last fifty-two weeks is twenty-seven dollars and eighty-three cents[5]. -
Pfizer's stock (PFE) is currently trading at twenty-six dollars and eighty cents as of January 13, 2025[4]. The trading volume has been slightly elevated, with 23,366,592 million shares traded on January 13, 2025, which is marginally below the average daily volume[4].
Recent news includes Pfizer's announcement of a $1.5 million Request for Proposals (RFP) on January 3, 2025, focusing on advancing care for patients with advanced prostate cancer. This initiative demonstrates Pfizer's continued commitment to oncology treatment development, though it has had limited immediate impact on the stock price[1].
Major analyst updates include UBS setting a price target of twenty-nine dollars on January 8, 2025, expecting PFE to rise within twelve months, indicating a possible 8.86% upside[2]. The consensus price target among 24 analysts is thirty-seven dollars, with the highest target being sixty dollars issued by Goldman Sachs on December 13, 2022, and the lowest being twenty-five dollars issued by Wolfe Research on November 15, 2024[2].
Other relevant information includes Pfizer's strong product lineup and promising new treatments and vaccines, which underpin a cautiously optimistic outlook for Pfizer's stock[3]. However, the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors can influence stock trajectories.
Technical indicators present a mixed outlook for PFE. Shorter-term moving averages suggest buying opportunities, while longer-term indicators paint a more cautious picture. The stock's current Relative Strength Index (RSI) of 54.26 indicates moderate buying momentum, and the Moving Average Convergence Divergence (MACD) reading of 0.1 supports a bullish short-term outlook[1].
In summary, Pfizer's stock shows potential for growth, with analysts projecting an average 12-month price target of thirty-two dollars, representing an 18.87% upside from current levels[5]. However, recent trading activity and technical indicators suggest possible near-term volatility. -
Pfizer's stock price as of January 7, 2025, is $26.59, showing moderate activity with an intraday range of $26.52 to $26.84. The trading volume remains slightly elevated at 33.40 million shares, marginally above the average daily volume of 33.15 million shares, indicating sustained investor interest[2].
Recent news includes Pfizer's announcement of a $1.5 million Request for Proposals (RFP) on January 3, focusing on advancing care for patients with advanced prostate cancer. This initiative demonstrates Pfizer's continued commitment to oncology treatment development, though it has had limited immediate impact on the stock price[2].
Major analyst updates include UBS setting a price target of $29.00 on January 8, 2025, expecting PFE to rise within 12 months, indicating a possible 8.86% upside. The consensus price target from 24 analysts is $37, with the high being $60 issued by Goldman Sachs on December 13, 2022, and the low being $25 issued by Wolfe Research on November 15, 2024[3].
Pfizer's valuation appears relatively attractive compared to its peers, with a P/E ratio of 35.93, significantly below the market average of 112.99 and the medical sector average of 87.73. The PEG ratio of 0.63 suggests potential undervaluation, while the P/B ratio of 1.68 indicates reasonable pricing relative to the company's assets[2].
Long-term forecasts vary significantly. CoinPriceForecast expects strong growth, suggesting Pfizer stock may reach $38.18 by 2028, while WalletInvestor predicts a possible decline to at least $15.164. PandaForecast anticipates sustained growth throughout 2025, with highs above $30 and reaching around $40.15 by December[4][5].
Overall, Pfizer's stock shows mixed signals amid market activity and recent announcements. While technical indicators present a cautious picture, analyst sentiment remains predominantly positive, with a consensus "Buy" rating and an average 12-month price target of $32.31, projecting a potential upside of 21.42% from current levels[2][3]. -
Pfizer's stock price as of January 13, 2025, is approximately twenty-six dollars and fifty-six cents. The trading volume is not specified in the provided sources, but we can analyze recent news and analyst updates.
Pfizer recently announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with Bacillus Calmette-Guérin (BCG) for patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). This development could potentially lead to regulatory filings and commercial success[3].
Analyst updates include UBS Group lowering its price target from thirty-one dollars to twenty-nine dollars, while Truist Financial reduced its target from thirty-six dollars to thirty-two dollars. Guggenheim also lowered its target from thirty-five dollars to thirty-three dollars. The average twelve-month price target from sixteen analysts is thirty-two dollars, indicating an eighteen point eight seven percent upside from the current price[2][4].
Long-term forecasts vary, with WalletInvestor predicting a slight decline in 2025, ranging from twenty-three dollars and eighty-three cents to twenty-eight dollars and ten cents. In contrast, CoinPriceForecast expects strong growth, suggesting the stock may reach thirty-eight dollars and eighteen cents by 2028[5].
In terms of recent price forecasts, Pfizer's stock is expected to fluctuate in the coming months. For January 2025, the forecast ranges from twenty-four dollars and forty-four cents to twenty-eight dollars and sixty-eight cents. The stock is predicted to rise gradually throughout the year, with forecasts for February, March, and April indicating increases[1].
Overall, Pfizer's stock shows potential for growth, driven by its strong product lineup and promising new treatments. However, investors should be cautious of regulatory shifts, competitive dynamics, and broader economic factors that can influence stock trajectories. -
Pfizer's stock price as of January 8, 2025, is $26.86[1]. The current price is below the 52-week high of $31.54 and above the 52-week low of $24.48, indicating a moderate position within its recent trading range.
Recent trading volume data is not provided in the available sources, but it is crucial to consider this factor for a comprehensive analysis. Typically, high trading volumes compared to the average can indicate significant investor interest or potential volatility.
There are no recent news or announcements about Pfizer or its stock mentioned in the provided sources. However, analyst updates and price target changes are available. The consensus price target among analysts is $32.00, with a forecasted upside of 18.87% from the current price[2]. Some analysts, such as Truist Securities, have set a price target of $32.00, expecting a 19.54% upside within the next 12 months[3].
Other forecasts vary significantly. CoinPriceForecast predicts a price range of $31.12 to $31.61 in 2025, indicating steady growth[4]. In contrast, PandaForecast anticipates a broader range of $26.46 to $40.15, with significant increases throughout the year[4]. LongForecast provides a detailed monthly forecast for 2025, starting with a range of $24.20 to $29.21 in January and ending with a range of $35.69 to $41.89 in December[5].
In summary, Pfizer's stock is currently trading at $26.86, with analysts predicting a potential upside of 18.87% to $32.00. Various forecasts suggest a range of possible outcomes, from steady growth to significant increases throughout 2025. Investors should consider these predictions along with recent trading volumes and any upcoming news or announcements for a comprehensive understanding of Pfizer's stock performance. -
Pfizer's stock, trading under the symbol PFE, has been a subject of interest for investors and analysts alike. As of January 11, 2025, the most recent closing stock price for Pfizer is 26.86 dollars[1].
In terms of trading volume, specific data on the current trading volume versus the average is not provided in the available sources. However, historical data indicates that Pfizer's stock has experienced fluctuations in trading volume, which can be influenced by various market and company-specific factors.
Recent news and announcements about Pfizer include the company's ongoing efforts in the pharmaceutical industry, particularly in developing new treatments and vaccines. However, specific recent news or announcements are not detailed in the provided sources.
Major analyst updates and price target changes include a consensus price target of 32 dollars, representing an 18.87% upside from the current price, according to 16 analysts[2]. Another source indicates a consensus price target of 37.09 dollars based on the ratings of 24 analysts, with the high being 60 dollars issued by Goldman Sachs and the low being 25 dollars issued by Wolfe Research[3].
Other relevant information includes forecasts from various sources. WalletInvestor predicts a slight decline in Pfizer stock in 2025, with a forecast ranging from 23.837 to 28.105 dollars[4]. In contrast, PandaForecast anticipates sustained growth throughout 2025, with prices potentially reaching 40.15 dollars by December[4]. LongForecast provides a detailed monthly forecast for 2025, indicating a steady increase in the stock price, starting from 26.53 dollars in January and reaching 38.79 dollars by December[5].
Overall, Pfizer's stock forecast is cautiously optimistic, with analysts anticipating potential growth driven by the company's strong product lineup and promising new treatments and vaccines. However, investors should note the industry's sensitivity to regulatory shifts, competitive dynamics, and broader economic factors, which can influence stock trajectories. -
Pfizer's stock price as of January 10, 2025, is $26.94, with a 0.3% increase during mid-day trading. The company traded as high as $27.00 and last traded at $26.94, with 10,932,240 shares traded, a decline of 65% from the average session volume of 31,681,477 shares[5].
Recent trading volume has been lower than average. On January 8, 2025, 31,721,568 million shares traded, but by January 10, 2025, this number decreased to 10,932,240 shares[2][5].
Several analysts have recently updated their ratings and price targets for Pfizer. Wolfe Research initiated coverage with an "underperform" rating and a $25.00 price objective. Evercore ISI raised Pfizer to a "strong-buy" rating. Guggenheim reduced their price objective from $35.00 to $33.00 and set a "buy" rating. UBS Group reduced their price target from $31.00 to $29.00 and set a "neutral" rating. The company currently has an average rating of "Moderate Buy" and an average target price of $32.00[5].
Pfizer reported $18 billion in revenue and $1.06 earnings per share in the last quarter, beating revenue expectations by $3 billion and exceeding earnings estimates by $0.44[2].
The long-term outlook for Pfizer stock is cautiously optimistic, with potential growth driven by the company's strong product lineup and promising new treatments and vaccines. However, the industry is sensitive to regulatory shifts, competitive dynamics, and broader economic factors[4].
Analysts predict a range of outcomes for Pfizer's stock price in 2025, from a decline to $24.897 by WalletInvestor to an increase to $31.61 by CoinPriceForecast and $40.15 by PandaForecast[4]. The average 12-month price forecast from 12 analysts is $32.17, predicting a 19.77% increase from the current stock price[3]. -
Pfizer (PFE) Stock Shows Mixed Signals Amid Healthcare Conference and FDA AI Guidance
In recent trading, Pfizer's stock continues to face pressure following its decline to $26.86 earlier this week. The pharmaceutical giant, currently valued at $152.02 billion, has seen significant trading volume with 31.7 million shares changing hands, reflecting ongoing market interest despite recent price weakness.
The company's participation in this week's healthcare conference, where executives discussed future strategies and pipeline developments, has drawn attention from investors and analysts alike. The webcast event, which was made public, highlighted Pfizer's commitment to transparency and stakeholder engagement during a crucial period for the company.
Adding to the sector's dynamics, the FDA's recent release of its first draft guidance on AI implementation in drug and medical device development has created both opportunities and challenges for pharmaceutical companies. This regulatory development could significantly impact Pfizer's research and development processes moving forward.
Wall Street remains generally optimistic about Pfizer's prospects, with 13 analysts maintaining a consensus Buy rating. Their average target price of $32.17 suggests a potential upside of 19.77% from current levels, though individual price targets show considerable variation, ranging from $25 to $45.
Long-term projections for Pfizer present contrasting views. While CoinPriceForecast anticipates the stock reaching $38.18 by 2028, WalletInvestor offers a more conservative outlook, suggesting a possible decline to $15.16. This disparity reflects the uncertainty surrounding the pharmaceutical sector's future landscape.
Pfizer's substantial market presence and diverse product portfolio continue to provide stability, though the stock faces headwinds from broader market conditions and industry-specific challenges. The company's ongoing efforts in research and development, particularly in emerging therapeutic areas, remain crucial factors for potential future growth.
Investors and analysts are closely monitoring Pfizer's response to recent regulatory developments and its ability to maintain market share in key therapeutic areas. The company's adaptation to new FDA guidelines regarding AI implementation could prove pivotal in maintaining its competitive edge in drug development and commercialization.
Trading activity suggests continued market interest in Pfizer, though price movement indicates cautious sentiment among investors. As the healthcare sector navigates evolving regulatory frameworks and technological advancements, Pfizer's strategic positioning and execution will be critical in determining its stock performance through 2025 and beyond. - Mostrar más
